Below is Validea's guru fundamental report for AMBRX BIOPHARMA INC (AMAM). Of the 22 guru strategies we follow, AMAM rates highest using our P/B Growth Investor model based on the published strategy ...
Ambrx Biopharma is a biotech company with an advanced approach to antibody-drug conjugates (ADCs) for oncology. Their proprietary platform for expanded genetic code technology creates ADCs for ...
In recent trading, shares of New Ambrx Biopharma Inc (Symbol: AMAM) have crossed above the average analyst 12-month target price of $22.86, changing hands for $27.47/share. When a stock reaches the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback